Allogeneic hematopoietic stem cell transplantation for dyskeratosis congenita

Shaimaa Elmahadi, Hideki Muramatsu, Seiji Kojima
In: Current Opinion in Hematology · 2016 · vol. 23(6) , pp. 501–507 · doi:10.1097/moh.0000000000000290 · PMID:27607446 · W2507791653
review OA: closed CC0
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-10 ⓘ

This review summarizes HSCT for dyskeratosis congenita, finding poor long-term survival mainly due to pulmonary complications, and suggests danazol as a potential first-line therapy.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

PURPOSE OF REVIEW: Dyskeratosis congenita is an inherited bone marrow failure syndrome caused by defects in telomere maintenance. Hematopoietic stem cell transplantation (HSCT) is the only curative treatment for bone marrow failure because of dyskeratosis congenita. The present review summarizes the literature with respect to the diagnosis and treatment of patients with dyskeratosis congenita who received HSCT, and discusses the recent progress in the management of dyskeratosis congenita. RECENT FINDINGS: The recent systematic review of the literature showed poor long-term outcome, with 10-year survival estimates of only 23% in 109 patients with dyskeratosis congenita who received HSCT. Multivariate analysis identified age greater than 20 years at HSCT, HSCT before 2000, and alternative donor source to be poor prognostic markers. HSCT for dyskeratosis congenita is characterized by a marked decline in long-term survival because of late deaths from pulmonary complications. However, a prospective study using danazol showed promising results in gain in telomere length and hematologic responses. SUMMARY: A recent prospective study may support the recommendation that HSCT is not indicated for patients with dyskeratosis congenita; instead, they should receive androgen, particularly danazol, as a first-line therapy. Another option may be routine use of androgen after HSCT for the prophylaxis of pulmonary fibrosis.

My notes (saved in your browser only)

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (2)

References (54)

Source provenance

openalex
last seen: 2026-05-11T06:14:16.517584+00:00
unpaywall
last seen: 2026-09-20T06:29:17.529187+00:00
License: CC0 · commercial use OK